We aimed to assess the association between adherence to guideline-recommended preventive medications and in-hospital mortality among this high-risk patient population. Evidence of the impact of acute pharmacological interventions in non-reperfused STEMI patients on subsequent events is limited. New risk stratification tools for patients with type 2 MI could guide risk-based monitoring and post-discharge care and improve patient categorization for clinical trials.Background and aims: Acute ST-elevation myocardial infarction (STEMI) is a potentially fatal presentation of coronary artery disease (CAD). In this study cohort, only 1.7% of patients underwent revascularization, and the use of secondary prevention medications was relatively low (aspirin, 69% P2Y12 inhibitors, 11% statins, 71% beta blockers, 65%). The limited value of the GRACE and TIMI scores in patients with type 2 MI might be attributable to the fact that such patients tend to be older and have a greater comorbidity burden than the type 1 MI cohorts from which the scores were derived.Īnother problem might be the less frequent use of traditional type 1 MI therapies by patients with type 2 MI. MACE (a composite of cardiovascular mortality, stroke and recurrent type 1 or type 2 MI): The TIMI score modestly predicted 30-day MACE but not MACE in-hospital or at 90 days the GRACE and TARRACO scores did not predict MACE.Cardiovascular Mortality: The TIMI and GRACE scores were modestly predictive the TARRACO score was not predictive.

All-cause Mortality: The GRACE score modestly predicted in-hospital, 30-day and 90-day mortality the other two scores were not predictive.The researchers found the following predictive value of the scores: The average GRACE, TIMI and TARRACO scores were 140, 3.7 and 4.9, respectively. The team reviewed 359 patients at Mass General who had a diagnosis of type 2 MI between October 2017 and May 2018 and were confirmed by the researchers to meet criteria for type 2 MI according to the 2018 Fourth Universal Definition of MI. In the Journal of the American College of Cardiology, they report that all three risk scores exhibited poor to modest ability to predict mortality or major adverse cardiovascular events (MACE) in type 2 MI. Wasfy, MD, MPhil, medical director of the Massachusetts General Physicians Organization and director of Quality and Analytics in the Cardiology Division at Massachusetts General Hospital, and colleagues were recently the first to compare the performance of the GRACE, TIMI and TARRACO scores in patients with type 2 MI. Sean Murphy, MB, BCh, BAO, internal medicine resident, Jason H. The TARRACO score joins the Global Registry of Acute Coronary Events (GRACE) and Thrombolysis in Myocardial Infarction (TIMI) risk scores, which are validated to predict adverse outcomes in patients with type 1 MI. It considers cardiac troponin concentration, age, hypertension, chest pain, dyspnea and anemia.Įrror: Please enter a valid email address.

In February 2019, researchers from the Joan XXIII University Hospital in Tarragona, Spain described in The American Journal of Medicine a new validated bedside tool, the TARRACO risk score, for predicting which patients with type 2 myocardial infarction (MI) are at the highest risk of adverse events. Better risk stratification tools are needed for patients with type 2 myocardial infarction.The TIMI score modestly predicted major adverse cardiovascular events (MACE) within 30 days but not MACE in-hospital or at 90 days the GRACE and TARRACO scores did not predict MACE.The TIMI and GRACE scores were modestly predictive of cardiovascular mortality, but the TARRACO score was not predictive.The GRACE score modestly predicted in-hospital, 30-day and 90-day all-cause mortality the other two scores were not predictive.

In a retrospective cohort of 359 patients with type 2 myocardial infarction, the average GRACE, TIMI and TARRACO scores were 140, 3.7 and 4.9, respectively.

Timi score aspirin